Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
- Conditions
- Recurrent Prostate CarcinomaStage III Prostate Cancer AJCC V8Stage IVA Prostate Cancer AJCC V8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed Tomography AngiographyRadiation: Radiation Therapy
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 72
- Registration Number
- NCT06650579
- Locations
- 🇺🇸
Emory Proton Therapy Center, Atlanta, Georgia, United States
🇺🇸Winship at Emory Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
- Conditions
- High Risk Prostate CarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Localized Prostate Adenocarcinoma
- Interventions
- Drug: Gonadotropin Releasing Hormone Agonists and AntagonistsProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Bone Scan
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT06528210
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma
- Conditions
- Recurrent GlioblastomaRecurrent High-grade Glioma
- Interventions
- Radiation: Intensity-modulated radiation therapy (IMRT)
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 30
- Registration Number
- NCT06501911
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 53
- Registration Number
- NCT06365788
- Locations
- 🇧🇪
Antwerp University Hospital, Antwerp, Belgium
🇧🇪Gasthuiszusters Antwerpen, Antwerp, Belgium
🇧🇪University Hospital Brussels, Brussel, Belgium
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 28
- Registration Number
- NCT06222593
- Locations
- 🇺🇸
UB/ Great Lakes Cancer Care, Buffalo, New York, United States
A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.
- Conditions
- Metastatic Urothelial Carcinoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- CHU de Quebec-Universite Laval
- Registration Number
- NCT06018116
- Locations
- 🇨🇦
CHU de Québec - Université Laval, Québec, Canada
Bicalutamide Therapy in Young Women With NAFLD and PCOS
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 50
- Registration Number
- NCT05979389
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2
- Conditions
- Polycystic Ovary SyndromeMetabolic DiseaseAndrogen Excess
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Royal College of Surgeons, Ireland
- Target Recruit Count
- 16
- Registration Number
- NCT05647356
- Locations
- 🇮🇪
Royal Collage Of Surgeons, Dublin, Ireland
Phase II Dutasteride in Combination With CAB vs CAB in SDC
- Conditions
- Salivary Duct Carcinoma
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT05513365
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Gelderland, Netherlands
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
- Conditions
- Non-Muscle Invasive Bladder Cancer
- Interventions
- Biological: Control Arm
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- CHU de Quebec-Universite Laval
- Target Recruit Count
- 160
- Registration Number
- NCT05327647
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
🇨🇦University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦Centre intégré de santé et services sociaux de Chaudière Appalaches, Lévis, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.